GlassScriptPhysician profile
Kevin L Jansen
NPI 1013908995
$2,519.77
in general payments reported to CMS, 2019-2025
31 companies · $571 in 2025
The $571 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $86.62 · 2021: $218 · 2022: $430 · 2023: $482 · 2024: $388 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,440.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $306.05 | 2019-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $250.42 | 2020-2023 | Lokelma, Evusheld, Farxiga |
| Travere Therapeutics, INC. | $234.50 | 2019-2025 | |
| Vifor Pharma, INC. | $215.99 | 2019-2024 | Veltassa |
| Fresenius USA Marketing, INC. | $187.09 | 2019-2025 | Velphoro |
| Amgen INC. | $174.48 | 2019-2025 | Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.62 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $108.24 | 2022-2024 | |
| Horizon Therapeutics Plc | $99.71 | 2019-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $98.46 | 2022-2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $89.53 | 2022-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $80.87 | 2021-2025 | Benlysta |
| Ardelyx, INC. | $73.92 | 2024-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $66.14 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $45.53 | 2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $43.44 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $36.70 | 2022-2025 | |
| Veloxis Pharmaceuticals, INC. | $35.51 | 2025 | Envarsus |
| Lilly USA, LLC | $30.71 | 2024 | Jardiance |
| Nevro Corp. | $29.69 | 2023 | Senza |
| Apellis Pharmaceuticals, INC. | $23.84 | 2025 | Empaveli |
| Janssen Pharmaceuticals, INC | $23.74 | 2019 | |
| Novo Nordisk INC | $21.23 | 2025 | Rybelsus, Ozempic |
| Mallinckrodt Enterprises LLC | $21.01 | 2019 | |
| Alnylam Pharmaceuticals INC. | $19.91 | 2021 | |
| Alexion Pharmaceuticals, INC. | $18.40 | 2024 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $16.99 | 2024 | Livtencity |
| Nxstage Medical, INC. | $15.73 | 2024 | |
| Boston Scientific Corporation | $14.44 | 2021 | |
| Genzyme Corporation | $13.90 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $12.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Jansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.